EVALUATION OF STABILITY OF ROPINIROLE HYDROCHLORIDE AND PRAMIPEXOLE DIHYDROCHLORIDE MICROSPHERES AT ACCELERATED CONDITION
Objective: The objective of the present work was to conduct accelerated stability study as per international council for harmonisation (ICH) guidelines and to establish shelf life of controlled release dosage form of ropinirole hydrochloride and pramipexole dihydrochloride microspheres for a period of 6 mo.
Methods: Most optimized batch of ropinirole hydrochloride and pramipexole dihydrochloride (F12 and M12 respectively) were selected and subjected to exhaustive stability testing by keeping the sample in stability oven for a period of 3 and 6 mo. Various parameters like surface morphology, particle size, drug content, in vitro drug release and shelf life were evaluated at 3 and 6 mo period. The surface morphology of the formulated microspheres was determined by scanning electron microscopy (SEM). The particle size of the microspheres was estimated by optical microscopy method. The drug content was assayed by the help of ultra-violet spectrophotometer (UV). The in vitro drug release was performed by using Paddle II type dissolution apparatus and the filtrate was analyzed by UV spectrophotometer. The shelf life of the optimized microspheres was calculated by using the rate constant value of the zero-order reaction.
Results: A minor change was recorded in average particle size of F12 and M12 microspheres after storage for 6 mo. For F12 and M12, initially the particle size was 130.00 Âµm and 128.92 Âµm respectively and after 6 mo it was found to be 130.92 Âµm and 128.99 Âµm respectively. There was no change in surface morphology of F12 and M12 microspheres after 6 mo of storage. The shape of microspheres remained spherical and smooth after 6 mo. An insignificant difference of drug content was recorded after 6 mo compared to the freshly prepared formulation. For F12 and M12, 94.50% and 93.77% of the drug was present initially and after 6 mo 94.45% and 93.72% of the drug was recorded. In vitro drug release was recorded after 6 mo for F12 and M12. Initially, 97.99% and 97.69% of the drug was released till 14th hour respectively for F12 and M12. After 6 mo, 98.23% and 97.99% of the drug was released respectively. The percentage residual drug content revealed that the degradation of microspheres was low. Considering the initial percentage residual drug content as 100%, 99.94% of the drug was recorded for both F12 and M12. The shelf life for F12 and M12 was found to be 10 y 52 d and 10 y 70 d respectively which were determined by the zero-order kinetic equation.
Conclusion: A more or less similar surface morphology, particle size, drug content and percent of drug release before and after stability study confirmed the stability of F12 and M12 microspheres after storage for 6 mo and prove the efficacy of the microspheres in the site-specific delivery of drugs in Parkinsonâ€™s disease.
2. Carstensen JT, Rhodes CT. Rationale policies for stability testing. Clin Res Regulatory Affairs 1993;10:177-85.
3. Puthli SP, Vavia PR. Stability studies of micro-particulate system with piroxicam as model drug. AAPS Pharm Sci Tech 2009;10:872â€“80.
4. Saffari M, Shahbazi M, Ardestani MS. Formulation and in vitro evaluation of Eudragit L100 microspheres of piroxicam. Nature Prec 2008;1:1544â€“7.
5. Azeem A, Iqbal Z, Ahmad FJ, Khar RK, Talegaonkar S. Development and validation of a stability-indicating method for determination of ropinirole in the bulk drug and in pharmaceutical dosage forms. Acta Chromatogr 2008;20:95â€“107.
6. Kim BK, Hwang SJ, Park JB, Park HJ. Preparation and characterization of drug-loaded polymethacrylate microspheres by an emulsion solvent evaporation method. J Microencapsul 2002;19:811â€“22.
7. Deshmukh M, Mohite S. Formulation and characterisation of olanzepine loaded mucoadhesive microspheres. Asian J Pharm Clin Res 2017;10:249-55.
8. Durgapal S, Mukherjee S, Goswami L. Preparation, characterization and evaluation of floating microparticles of ciprofloxacin. Int J Appl Pharm 2017;9:1-8.
9. Guideline IH. Stability testing guidelines: stability testing of new drug substances and products. ICH Q1A (R2) (CPMP/ICH/2736/99); 1999.
10. Singh S. Stability testing during product development. In: Jain NK. Pharmaceutical product development. CBS publisher and distributors India; 2000. p. 272-93.
11. Kommanaboyina B, Rhodes CT. Trends in stability testing, with emphasis on stability during distribution and storage. Drug Dev Ind Pharm 1999;25:857-67.
12. Tyagi LK, Kori ML. Stability study and in vivo evaluation of lornoxicam loaded ethyl cellulose microspheres. Int J Pharm Sci Drug Res 2014;6:26-30.
13. Sharma M, Kohli S, Pal A. Stability of floating microspheres at normal and accelerated conditions. Int J Pharm Pharm Sci 2016;8:452-4.
14. Puthli SP, Vavia PR. Stability indicating HPTLC determination of piroxicam. J Pharm Biomed Anal 2000;22:673â€“7.
15. Bajaj S, Singhla D, Sakhuja N. Stability testing of pharmaceutical products. J Appl Pharm Sci 2012;2 Suppl 3:129-38.
16. Johansen P, Men Y, Audran R, Corradin G, Merkle HP, Gander B. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm Res 1998;15:1103â€“10.
17. Singh S, Bakshi M. Guidance on the conduct of stress test to determine the inherent stability of drugs. Pharm Technol Asia 2000;24:1-14.
18. Kohli S, Pal A, Jain S. Preparation, characterization and evaluation of Poly (Lactide-co-Glycoside) microsphere for the controlled release of zidovudine. Int J Pharm Pharm Sci 2017;9:70-7.
19. Sayin B, Calis S. Influence of accelerated storage conditions on the stability of vancomycin loaded poly (D, L-Lactide-co-glycolide) microspheres. FABAD J Pharm Sci 2004;29:111-6.
20. Dunne M, Corrigan OI, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 2000;21:1659â€“68.
21. Chacon M, Molpeceres J, Berges L, Guzman M, Aberturas MR. Stability and freeze drying of cyclosporine loaded poly (D, L lactide-glycolide) carriers. Eur J Pharm Sci 1999;8:99-107.
22. Donnell PB, McGinity JW. Influence of processing on the stability and release properties of biodegradable microspheres containing thioridazine hydrochloride. Eur J Pharm Biopharm 1998;45:83-94.
23. Delgado A, Evora C, Llabres M. Effect of storage on the stability of DL-PLA microspheres containing methadone. Int J Pharm 1998;166:223-5.
24. Lewis L, Boni RL, Adeyeye CM. The physical and chemical stability of suspensions of sustained-release diclofenac microspheres. J Microencapsulation 1998;15:555-67.
25. Carstensen JT. Drug stability, principles and practices. 2nd ed. New York: Marcel Dekker Publishers; 2000.
26. Singh S. Drug stability testing and shelf-life determination according to international guidelines. Pharm Technol 1999;23:68-88.